Search
Dec 12, 2024
Seattle based Lumen Bioscience is using the cyanobacteria spirulina to manufacture medicines, which might increase the yield and lower the cost of biologics. Its pipeline includes an obesity program
CEO Brian Finrow describes the characteristics of spirulina that Lumen believes will make it the next new paradigm in developing and...
Dec 11, 2024
Seattle based Umoja Biopharma is a pioneer of in vivo CAR-T cell engineering. CEO Andrew Scharenberg describes the technical innovations they have come up with to help make it succeed
He describes Umoja's numerous platforms that are aimed at maximizing in vivo success, including the company's proprietary lentiviral...
Dec 10, 2024
ASH 2024: France's MaaT Pharma presented early access data at ASH for its microbiome based treatment for GvHD - a formal study will read out early next year
CMO Gianfranco Pittari describes the unmet neet in GvHD and how the donor derived microbiome treatment is designed to work. A patient has...
Dec 10, 2024
ASH 2024: Nurix Therapeutics' CEO Arthur Sands talks BTK degradation vs inhibition and the company's broader pipeline of degraders
He discusses Nurix's clinical data set that was presented at ASH. Plus, the company's pipeline, including in the autoimmune space, and...
Dec 10, 2024
ASH 2024: Disc Medicine's CEO shares an update on three programs, including an oral presentation for an anti-anemia antibody for patients with myelofibrosis and potentially beyond in the future
John Quisel shares an update on ASH data for DISC-0974, bitopertin, and DISC-3405.
Dec 9, 2024
Neurvati Neurosciences is a Blackstone owned development company that focuses on late stage assets in neuroscience - the first project targets an NMDA subunit, called NR2B, for GRIN disorders
CEO Bruce Leuchter, a physician trained in neurology and psychiatry himself, describes the rational and structure behind Neurvati, and...
Dec 9, 2024
ASH 2024: Legend CEO Ying Huang on moving Carvykti into earlier settings, potential future competition, beyond BCMA, and more
He discusses this year's Cartitude 4 approval, plus current studies in 1L multiple myeloma. Also, his take on a potential future...
Dec 9, 2024
The CEO of Lyndra Therapeutics describes the company's technology that turns daily pills into weekly ones - and potentially longer
Jessica Ballinger describes the science behind this and how an extended release format can improve health outcomes. Plus, the progress...
Dec 9, 2024
ASH 2024: Kura Oncology CEO Troy Wilson highlights combination data in 1L AML for the menin inhibitor ziftomenib
He describes the data Kura has presented at ASH and where he believes it puts the company in the competive picture, including why 1L is...
Dec 8, 2024
ASH 2024: Kite Pharma's global head discusses the progress of the CAR-T field, Arcellx's BCMA data, cures in CD19, autoimmune, and future targets
Cindy Perettie describes why she took the head job at Kite a little over a year ago, long-term CD19 data, tonight's BCMA update, Kite's...
Dec 8, 2024
ASH 2024: Arcellx CEO Rami Elghandour discusses a data update of the iMMagine-1 Study for the company's BCMA CAR-T
The data showed a 62% CR/sCR at a median follow-up of 9.5 months. He discusses the patient population, next steps, and the work that...
Dec 8, 2024
ASH 2024: Beam's CEO John Evans on the company's based editing sickle cell data, and preclinical data on a next generation product meant to broaden the potential patient population
He describes clinical data presented at ASH for BEAM-101 and how he believes it stacks up against competition that is on the market....
Dec 8, 2024
ASH 2024: Incyte CEO Hervé Hoppenot on the company's hematology franchise and keeping up the momentum in 2025
He comments on data at ASH including tafasitamab, axitilimab, and the company's BET inhibitor. Plus, news from yesterday on Incyte's PD1,...
Dec 8, 2024
ASH 2024: BeiGene CEO John Oyler on degraders, long-term BTK data, BCL2 inhibition, and being a global company
He describes the different profile of degraders vs small molecules, and highlights BeiGene's programs in BTK, EGFR, IRAK4, and others....
Dec 7, 2024
ASH 2024: Autolus CEO Christian Itin talks about the approval of of the CAR-T Aucatzyl, as well as the company's development pipeline (including autoimmune)
He discusses Autolus' 'fast off' approach to CAR-T and why he believes the safety benefits led to no REMS requirement for Aucatzyl. Plus,...
Dec 7, 2024
ASH 2024: Cambridge, UK based CellCentric has a unique approach to targeting p300/CBP and thus reducing the activation of oncogenes like IRF4 and MYC in multiple myeloma
CEO Will West describes how the company focuses on inhibiting the bromodomain of these targets with inobrodib, rather than the active...
Dec 7, 2024
ASH 2024: The new CEO of Innate Pharma on taking the job and the company's work on antibodies, engagers, and ADCs
Jonathan Dickinson describes what appealed to him about Innate. He discusses the pipeline, including ASH data from the lead program...
Dec 7, 2024
Janux's CEO David Campbell reviews this week's data from JANX007, the company's PSMA x CD3 masked bispecific for prostate cancer
He describes how the improvement over data from earlier this year gives him confidence in the strength of the signal he sees in this...
Nov 28, 2024
The Co-Founder and CTO of Seoul based Organoid Sciences walks us through how the company is using organoids for regenerative medicine, CRO services, and precision medicine
KyungJin Lee explains how Organoid Sciences is turning its expertise in organoids into a diversified business, and how it has been...
Nov 27, 2024
The CEO of Seoul based Bridge Biotherapeutics discusses the importance of drug development experience - a lead program in IPF is scheduled to have a key phase 2 readout next spring
CEO Jame Lee, a founder of multiple biotech companies, describes the operational experience that he suggests is a key differentiator for...
.png){kind=logo}
